Written Question·Department of Health and Social Care·UIN HL15395
Liothyronine: Prices
Tabled: 10 March 2026
Answered: 23 March 2026
Question
To ask His Majesty's Government what assessment they have made of the Competition and Markets Authority's finding of excessive and unfair pricing in the supply of liothyronine tablets in the UK; and what progress they have made in discussions with manufac
Answer
There has been no assessment made of the Competition and Markets Authority’s findings, but no company should exploit the National Health Service. Anti-competitive behaviour, including excessive pricing, is a matter for the Competition and Markets Authorit...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN HL15395) →